Hepatitis D - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis D - Pipeline Review, H2 2016, provides an overview of the Hepatitis D (Infectious Disease) pipeline landscape.

Hepatitis D, also known as the delta virus, is an infection that causes liver to swell. It is caused by the hepatitis D virus (HDV). Symptoms include yellowing of skin and eyes, joint pain, abdominal pains, vomiting, loss of appetite and fatigue. Risk factors include receiving many blood transfusions, abusing intravenous (IV) or injection drugs and being infected while pregnant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hepatitis D - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hepatitis D (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis D (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 5, 4 and 2 respectively for Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively for Hepatitis D.

Hepatitis D (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis D (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis D (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis D (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis D (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis D (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis D (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis D (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hepatitis D Overview 7
Therapeutics Development 8
Pipeline Products for Hepatitis D - Overview 8
Pipeline Products for Hepatitis D - Comparative Analysis 9
Hepatitis D - Therapeutics under Development by Companies 10
Hepatitis D - Therapeutics under Investigation by Universities/Institutes 11
Hepatitis D - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Hepatitis D - Products under Development by Companies 15
Hepatitis D - Products under Investigation by Universities/Institutes 16
Hepatitis D - Companies Involved in Therapeutics Development 17
Alnylam Pharmaceuticals, Inc. 17
Arrowhead Pharmaceuticals, Inc. 18
Eiger BioPharmaceuticals, Inc. 19
F. Hoffmann-La Roche Ltd. 20
Globeimmune, Inc. 21
REPLICor Inc. 22
Rodos BioTarget GmbH 23
SomaGenics, Inc. 24
Spring Bank Pharmaceuticals, Inc. 25
Hepatitis D - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
ALN-HDV - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ARC-520 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
GI-18000 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
lonafarnib - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Myrcludex-B - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
peginterferon alfa-2a - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
peginterferon lambda-1a - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
RBT-05 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
REP-2139 - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
REP-2165 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
RNAi Oligonucleotide for Hepatitis D - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
SB-9200 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
vanitaracin A - Drug Profile 66
Product Description 66
Mechanism Of Action 66
R&D Progress 66
Hepatitis D - Dormant Projects 67
Hepatitis D - Product Development Milestones 68
Featured News & Press Releases 68
Sep 07, 2016: Eiger Announces Completion of Dosing in Phase 2 LOWR HDV - 4 Study at Hannover Medical School 68
Jul 20, 2016: Eiger BioPharmaceuticals Announces Completion of Dosing in Phase 2 LOWR HDV - 3 Study at National Institutes of Health 68
Jun 01, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Publication of Myrcludex B Clinical Results in Journal of Hepatology 69
May 25, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start Of Second Phase 2 Clinical Trial Of Myrcludex B In Chronic Hepatitis B/D Infection 69
Apr 29, 2016: Interim Results Of A Phase Ib/IIa Study Of The Entry Inhibitor Myrcludex B 69
Apr 04, 2016: Replicor to Make Three Presentations at EASL 2016 70
Mar 30, 2016: Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver Meeting 70
Mar 23, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection 71
Mar 14, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School 72
Jan 19, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV - 3 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 3) Study at National Institutes of Health 72
Jan 06, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School in Hannover, Germany 73
Jul 20, 2015: The Lancet Infectious Diseases Journal Publishes Results of Phase 2 Study of Lonafarnib in Hepatitis Delta Virus Infected Patients 73
Jun 30, 2015: Replicor Discloses Updated Clinical Trial Data to the Global Virus Hepatitis Summit in Berlin 73
Jun 10, 2015: Replicor to Present at the Israel Association for the Study of Liver Conference and the Global Virus Hepatitis Summit in Berlin in June 74
Apr 29, 2015: Significant Reduction of HBsAg and HDV RNA by REP 2139-Ca in Caucasian Patients with HBV / HDV Co-Infection 74
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables

Number of Products under Development for Hepatitis D, H2 2016 8
Number of Products under Development for Hepatitis D - Comparative Analysis, H2 2016 9
Number of Products under Development by Companies, H2 2016 10
Number of Products under Investigation by Universities/Institutes, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 12
Comparative Analysis by Clinical Stage Development, H2 2016 13
Comparative Analysis by Early Stage Development, H2 2016 14
Products under Development by Companies, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Hepatitis D - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 17
Hepatitis D - Pipeline by Arrowhead Pharmaceuticals, Inc., H2 2016 18
Hepatitis D - Pipeline by Eiger BioPharmaceuticals, Inc., H2 2016 19
Hepatitis D - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 20
Hepatitis D - Pipeline by Globeimmune, Inc., H2 2016 21
Hepatitis D - Pipeline by REPLICor Inc., H2 2016 22
Hepatitis D - Pipeline by Rodos BioTarget GmbH, H2 2016 23
Hepatitis D - Pipeline by SomaGenics, Inc., H2 2016 24
Hepatitis D - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016 25
Assessment by Monotherapy Products, H2 2016 26
Number of Products by Stage and Target, H2 2016 28
Number of Products by Stage and Mechanism of Action, H2 2016 30
Number of Products by Stage and Route of Administration, H2 2016 32
Number of Products by Stage and Molecule Type, H2 2016 34
Hepatitis D - Dormant Projects, H2 2016 67